Client Portal
Partner Craig Smith quoted
Article published in Massachusetts Lawyers Weekly
Craig R. Smith said the case highlights some of the issues in deciding whether to list a patent in the Orange Book.
“One of the dilemmas companies face is deciding what is considered a patent for a ‘drug’ or ‘drug product’ relating to the drug you’d gotten your initial patent on,” said Smith, an IP lawyer in Cambridge. “There’s a question of how do you comply with the regulation.”
Smith said that companies have asked the FDA for guidance on whether they should list a patent.
“They’ve never provided an answer that is clear enough for people to know for sure whether they should be filing or the approach they should take going forward,” Smith said.
SHARE THIS POST
